[ENTA] Enanta Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 34.53 Change: 1.51 (4.57%)
Ext. hours: Change: 0 (0%)

chart ENTA

Refresh chart

Strongest Trends Summary For ENTA

ENTA is in the medium-term down -37% below S&P in 1 year. In the long-term up 90% in 6 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Enanta Pharmaceuticals, Inc., a biotechnology company, is engaged in the development of small molecule drugs for the infectious disease field. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products comprising EDP-788 for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc.; and AbbVie Inc. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 36.42% Sales Growth - Q/Q-25.98% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA47.08% ROE51.63% ROI
Current Ratio8.98 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin82.62% Net Profit Margin64.48% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities2.26 M Cash From Investing Activities-100.46 M Cash From Operating Activities93.25 M Gross Profit
Net Profit28.75 M Operating Profit48.56 M Total Assets245.88 M Total Current Assets177.78 M
Total Current Liabilities19.79 M Total Debt180 K Total Liabilities21.67 M Total Revenue57.37 M
Technical Data
High 52 week105.66 Low 52 week57.95 Last close59.48 Last change2.09%
RSI24.08 Average true range3.15 Beta1.05 Volume182.38 K
Simple moving average 20 days-6.19% Simple moving average 50 days-11.99% Simple moving average 200 days-28.44%
Performance Data
Performance Week2.41% Performance Month-14.89% Performance Quart-27.21% Performance Half-35.06%
Performance Year-20.36% Performance Year-to-date-16.02% Volatility daily3.86% Volatility weekly8.64%
Volatility monthly17.71% Volatility yearly61.35% Relative Volume295.56% Average Volume208.95 K
New High0.99% New Low

News

2020-05-23 09:58:44 | If You Had Bought Enanta Pharmaceuticals NASDAQ:ENTA Stock Three Years Ago, You Could Pocket A 84% Gain Today

2020-05-14 08:53:12 | Why Enanta Pharmaceuticals ENTA Stock Might be a Great Pick

2020-05-12 07:30:00 | Enanta Pharmaceuticals to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

2020-05-09 21:43:21 | Were Hedge Funds Right About Enanta Pharmaceuticals Inc ENTA?

2020-05-07 01:37:58 | Edited Transcript of ENTA earnings conference call or presentation 6-May-20 8:30pm GMT

2020-05-07 00:01:27 | Enanta Pharmaceuticals Inc ENTA Q2 2020 Earnings Call Transcript

2020-05-06 18:45:10 | Enanta Pharmaceuticals ENTA Reports Q2 Loss, Misses Revenue Estimates

2020-05-06 16:03:00 | Enanta Announces Results of INTREPID Study of EDP-305 for the Treatment of Primary Biliary Cholangitis

2020-05-06 16:03:00 | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET

2020-04-29 12:34:04 | Analysts Estimate Enanta Pharmaceuticals ENTA to Report a Decline in Earnings: What to Look Out for

2020-04-28 16:05:00 | Enanta to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended March 31, 2020

2020-04-28 12:33:04 | Analysts Estimate Enanta Pharmaceuticals ENTA to Report a Decline in Earnings: What to Look Out for

2020-04-17 10:19:16 | Is Enanta Pharmaceuticals NASDAQ:ENTA Using Too Much Debt?

2020-03-26 16:05:00 | Enanta Provides Update on Clinical Development Activities During COVID-19 Pandemic

2020-03-13 07:00:00 | Enanta Pharmaceuticals Announces Efforts to Discover a Treatment for the Novel Coronavirus Disease COVID-19

2020-03-06 07:05:00 | Enanta’s HCV Collaboration Partner AbbVie Receives Marketing Authorization from European Commission to Shorten MAVIRET® glecaprevir/pibrentasvir Duration to Eight Weeks for Treatment-Naïve Genotype 3 HCV Patients with Compensated Cirrhosis

2020-03-04 08:09:24 | Does Market Volatility Impact Enanta Pharmaceuticals, Inc.'s NASDAQ:ENTA Share Price?

2020-02-10 18:29:44 | Edited Transcript of ENTA earnings conference call or presentation 6-Feb-20 9:30pm GMT

2020-02-06 17:15:10 | Enanta Pharmaceuticals ENTA Q1 Earnings Top Estimates

2020-02-06 16:00:00 | Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2019

2020-02-06 14:30:00 | Enanta Pharmaceuticals, Inc. to Host Earnings Call

2020-02-05 16:11:53 | 13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market

2020-02-03 07:27:17 | Is Enanta Pharmaceuticals, Inc.'s NASDAQ:ENTA High P/E Ratio A Problem For Investors?

2020-01-30 12:31:05 | Earnings Preview: Enanta Pharmaceuticals ENTA Q1 Earnings Expected to Decline

2020-01-24 07:30:00 | Enanta to Host Conference Call on February 6 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2019

2020-01-14 05:30:00 | AbbVie's MAVIRET® now listed on the Newfoundland and Labrador formulary

2020-01-09 07:30:00 | Enanta to Provide Updates on its R&D Programs and Business Outlook for 2020 during the 38th Annual J.P. Morgan Healthcare Conference

2020-01-04 08:44:15 | Does This Valuation Of Enanta Pharmaceuticals, Inc. NASDAQ:ENTA Imply Investors Are Overpaying?

2019-12-30 07:30:00 | Enanta Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

2019-12-11 11:25:24 | Is Enanta Pharmaceuticals Inc ENTA A Good Stock To Buy?

2019-12-09 07:38:17 | Should You Worry About Enanta Pharmaceuticals, Inc.'s NASDAQ:ENTA CEO Pay Cheque?

2019-11-27 00:09:34 | Edited Transcript of ENTA earnings conference call or presentation 21-Nov-19 9:30pm GMT

2019-11-22 08:18:08 | The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate

2019-11-21 17:15:10 | Enanta Pharmaceuticals ENTA Lags Q4 Earnings and Revenue Estimates

2019-11-21 16:00:00 | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019

2019-11-21 07:22:05 | The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon

2019-11-17 08:42:54 | The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down

2019-11-14 10:30:03 | Analysts Estimate Enanta Pharmaceuticals ENTA to Report a Decline in Earnings: What to Look Out for

2019-11-11 10:21:50 | Is Enanta Pharmaceuticals, Inc.'s NASDAQ:ENTA 14% ROE Worse Than Average?

2019-11-11 07:30:00 | Enanta Pharmaceuticals Announces Poster Presentations at The Liver Meeting® 2019

2019-11-05 16:00:00 | Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019

2019-10-27 22:29:08 | Enanta Pharmaceuticals Inc ENTA: Hedge Funds In Wait-and-See Mode

2019-10-21 16:00:00 | Enanta Pharmaceuticals to Present at the 2019 Wolfe Research Healthcare Conference

2019-10-12 10:03:32 | Is Enanta Pharmaceuticals's NASDAQ:ENTA Share Price Gain Of 145% Well Earned?

2019-10-03 07:34:18 | The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo

2019-10-03 07:30:00 | New Data from Enanta’s Phase 2a Human Challenge Study of EDP-938 for RSV Demonstrates Highly Statistically Significant Reductions p<0.001 in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay

2019-09-29 15:01:41 | The Week Ahead In Biotech Sept. 29-Oct. 5: Conference Presentations, IPOs Hit Top Gear

2019-09-26 16:16:41 | This Biotech Stock Just Careened Toward Its Lowest Point In Nearly 2 Years

2019-09-26 11:40:03 | Enanta's Stock Down Despite NASH Drug Meeting Goal in Study

2019-09-26 07:54:44 | The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J